close

Agreements

Date: 2017-03-20

Type of information: Nomination

Compound:

Company: Kiadis Pharma (The Netherlands)

Therapeutic area: Cancer - Oncology - Hematological diseases

Type agreement: nomination

Action mechanism:

Disease:

Details: * On March 20, 2017, Kiadis Pharma announced the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017. Jan Feijen has been Vice President Manufacturing and Technical Operations, Platform Lead Vaccines and Advanced Therapies at Janssen. Prior to that he held various executive and project lead positions at Crucell, Avebe and Gist Brocades. Jan has built and run many clinical and commercial manufacturing facilities and operations across multiple sites in Europe, the US and Asia. In his role as COO at Kiadis Pharma, Jan will be responsible for manufacturing, supply chain, QA and project management. Kiadis Pharma has recently initiated a pivotal Phase III trial with ATIR101™ (Allodepleted T-cell ImmunotheRapeutics). This therapy provides for a safe donor lymphocyte infusion from a partially matched (haploidentical) family member without the risk of causing severe Graft-versus-Host-Disease (GVHD). In ATIR101™, T-cells that would cause GVHD are eliminated from the donor lymphocytes using Kiadis Pharma’s photodepletion technology, minimizing the risk of GVHD and eliminating the need for prophylactic immune-suppression. At the same time, ATIR101™ contains potential cancer killing T-cells from the donor that could eliminate residual cancer cells and help prevent relapse of the disease, known as the Graft-versus-Leukemia (GVL) effect.

Financial terms:

Latest news:

Is general: Yes